Tyrosine Residues That Control Binding and Gating in the 5-Hydroxytryptamine3 Receptor Revealed by Unnatural Amino Acid Mutagenesis

The mechanism by which agonist binding triggers pore opening in ligand-gated ion channels is poorly understood. Here, we used unnatural amino acid mutagenesis to introduce subtle changes to the side chains of tyrosine residues (Tyr141, Tyr143, Tyr153, and Tyr234), which dominate the 5-HT3 receptor binding site. Heterologous expression in oocytes, combined with radioligand binding data and a model of 5-HT (serotonin) computationally docked into the binding site, has allowed us to determine which of these residues are responsible for binding and/or gating. We have shown that Tyr 143 forms a hydrogen bond that is essential for receptor gating but does not affect binding, whereas a hydrogen bond formed by Tyr153 is involved in both binding and gating of the receptor. The aromatic group of Tyr234 is essential for binding and gating, whereas its hydroxyl does not affect binding but plays a steric role in receptor gating. Tyr141 is not involved in agonist binding or receptor gating but is important for antagonist interactions. These data, combined with a new model of the nonliganded 5-HT3 receptor, lead to a mechanistic explanation of the interactions that initiate the conformational change leading to channel opening. Thus, we suggest that agonist entry into the binding pocket may displace Tyr143 and Tyr153 and results in their forming new hydrogen bonds. These bonds may form part of the network of bond rearrangements that trigger the conformational change leading to channel opening. Similar rearrangements may initiate gating in all Cys-loop receptors.

[1]  Y. Fujiyoshi,et al.  Activation of the nicotinic acetylcholine receptor involves a switch in conformation of the alpha subunits. , 2002, Journal of molecular biology.

[2]  J. Tytgat,et al.  Subunit stoichiometry of a mammalian K+ channel determined by construction of multimeric cDNAs , 1992, Neuron.

[3]  E. Kirkness,et al.  Evidence for Expression of Heteromeric Serotonin 5‐HT3 Receptors in Rodents , 2000, Journal of neurochemistry.

[4]  J. Changeux,et al.  Models of the extracellular domain of the nicotinic receptors and of agonist- and Ca2+-binding sites , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[5]  P. Chau,et al.  Prediction of 5-HT3 receptor agonist-binding residues using homology modeling. , 2003, Biophysical journal.

[6]  Zsolt Bikádi,et al.  Binding Interactions of Antagonists with 5‐Hydroxytryptamine3A Receptor Models , 2003, Journal of receptor and signal transduction research.

[7]  A. Auerbach,et al.  Gating Dynamics of the Acetylcholine Receptor Extracellular Domain , 2004, The Journal of general physiology.

[8]  S. Lummis,et al.  The molecular basis of the structure and function of the 5-HT 3 receptor: a model ligand-gated ion channel (Review) , 2002, Molecular membrane biology.

[9]  C. Taylor,et al.  Direct inhibition of 5-hydroxytryptamine3 receptors by antagonists of L-type Ca2+ channels. , 1996, Molecular pharmacology.

[10]  Matthew P. Anderson,et al.  Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive , 1992, Nature.

[11]  D. A. Dougherty,et al.  Different binding orientations for the same agonist at homologous receptors: a lock and key or a simple wedge? , 2003, Journal of the American Chemical Society.

[12]  J. Changeux,et al.  An H‐bond between two residues from different loops of the acetylcholine binding site contributes to the activation mechanism of nicotinic receptors , 2003, The EMBO journal.

[13]  Y. Fujiyoshi,et al.  Structure and gating mechanism of the acetylcholine receptor pore , 2003, Nature.

[14]  T. Sixma,et al.  Nicotine and Carbamylcholine Binding to Nicotinic Acetylcholine Receptors as Studied in AChBP Crystal Structures , 2004, Neuron.

[15]  R. Rupprecht,et al.  Molecular cloning, functional expression, and pharmacological characterization of 5-hydroxytryptamine3 receptor cDNA and its splice variants from guinea pig. , 1998, Molecular pharmacology.

[16]  Ruben Abagyan,et al.  Structural model of nicotinic acetylcholine receptor isotypes bound to acetylcholine and nicotine , 2002, BMC Structural Biology.

[17]  T. Sixma,et al.  Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors , 2001, Nature.

[18]  N. Davidson,et al.  Nicotinic receptor binding site probed with unnatural amino acid incorporation in intact cells. , 1995, Science.

[19]  P. Joshi,et al.  Identification of critical residues in loop E in the 5-HT3ASR binding site , 2002, BMC Biochemistry.

[20]  Michael W Parker,et al.  Anxiety over GABA(A) receptor structure relieved by AChBP. , 2002, Trends in biochemical sciences.

[21]  Kerry L. Price,et al.  The Role of Tyrosine Residues in the Extracellular Domain of the 5-Hydroxytryptamine3 Receptor* , 2004, Journal of Biological Chemistry.

[22]  Niki M Zacharias,et al.  Cation-pi interactions in ligand recognition by serotonergic (5-HT3A) and nicotinic acetylcholine receptors: the anomalous binding properties of nicotine. , 2002, Biochemistry.

[23]  H. Lester,et al.  In vivo incorporation of unnatural amino acids into ion channels in Xenopus oocyte expression system. , 1998, Methods in enzymology.

[24]  T. Kunkel.  Rapid and efficient site-specific mutagenesis without phenotypic selection. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[25]  R. Harris,et al.  A single amino acid of the human gamma-aminobutyric acid type A receptor gamma 2 subunit determines benzodiazepine efficacy. , 1994, The Journal of biological chemistry.

[26]  C. Czajkowski,et al.  Structure and Dynamics of the GABA Binding Pocket: A Narrowing Cleft that Constricts during Activation , 2001, The Journal of Neuroscience.